AstraZeneca (NASDAQ:AZN) Shares Unloaded Rep. Val T. Hoyle

Representative Val T. Hoyle (D-Oregon) recently sold shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in AstraZeneca stock on September 23rd. The trade occurred in the Representative’s “FIDELITY ROLLOVER IRA” account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marriott International (NASDAQ:MAR) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of H&R Block (NYSE:HRB) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of NIKE (NYSE:NKE) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Bank of New York Mellon (NYSE:BK) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Cisco Systems (NASDAQ:CSCO) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Pentair (NYSE:PNR) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Heico (NYSE:HEI.A) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Target (NYSE:TGT) on 9/23/2025.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $84.53 on Monday. The business has a 50-day moving average of $79.18 and a 200 day moving average of $73.46. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $86.57. The stock has a market capitalization of $262.16 billion, a price-to-earnings ratio of 31.78, a price-to-earnings-growth ratio of 1.55 and a beta of 0.36. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.AstraZeneca’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.24 EPS. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were issued a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date was Friday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is 37.97%.

Wall Street Analyst Weigh In

AZN has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $86.00.

Institutional Investors Weigh In On AstraZeneca

Several hedge funds and other institutional investors have recently made changes to their positions in AZN. NewSquare Capital LLC raised its position in shares of AstraZeneca by 149.3% during the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after acquiring an additional 218 shares in the last quarter. Larson Financial Group LLC raised its position in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after acquiring an additional 289 shares in the last quarter. Richardson Financial Services Inc. raised its position in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after acquiring an additional 149 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in AstraZeneca during the first quarter worth approximately $29,000. Finally, Costello Asset Management INC acquired a new position in AstraZeneca during the first quarter worth approximately $29,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon’s 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon’s 4th Congressional District. She declared candidacy for the 2026 election.

Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.